Nutex Health (NASDAQ:NUTX – Get Free Report) is expected to be posting its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to announce earnings of $4.95 per share and revenue of $215.0310 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 7, 2026 at 10:30 AM ET.
Nutex Health (NASDAQ:NUTX – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported $6.52 EPS for the quarter, beating the consensus estimate of $3.99 by $2.53. The company had revenue of $216.49 million for the quarter, compared to the consensus estimate of $227.80 million. Nutex Health had a net margin of 10.95% and a return on equity of 23.50%. On average, analysts expect Nutex Health to post $23 EPS for the current fiscal year and $24 EPS for the next fiscal year.
Nutex Health Price Performance
Shares of NUTX opened at $157.21 on Thursday. Nutex Health has a twelve month low of $77.21 and a twelve month high of $204.00. The company has a market capitalization of $1.08 billion, a P/E ratio of 12.15 and a beta of 0.21. The firm has a 50 day moving average of $150.63 and a 200 day moving average of $130.51. The company has a quick ratio of 3.12, a current ratio of 3.14 and a debt-to-equity ratio of 0.66.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
A number of research analysts have weighed in on the company. Wall Street Zen downgraded Nutex Health from a “strong-buy” rating to a “buy” rating in a report on Monday. B. Riley Financial assumed coverage on Nutex Health in a research report on Friday, June 26th. They set a “buy” rating and a $290.00 target price on the stock. Lake Street Capital initiated coverage on Nutex Health in a research report on Tuesday, June 2nd. They issued a “buy” rating and a $235.00 price target for the company. Weiss Ratings downgraded Nutex Health from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, July 10th. Finally, Zacks Research raised Nutex Health to a “hold” rating in a research report on Monday, June 29th. Three equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Nutex Health currently has a consensus rating of “Moderate Buy” and an average target price of $243.33.
Check Out Our Latest Research Report on Nutex Health
Nutex Health Company Profile
Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.
The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.
Featured Articles
- Five stocks we like better than Nutex Health
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Nutex Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutex Health and related companies with MarketBeat.com's FREE daily email newsletter.
